TRR-ACG1-2: A Potential Drug Target and Biomarker (G7231)

Target Name: TRR-ACG1-2

NCBI ID: G7231

TRR-ACG1-2

Other Name(s): Transfer RNA arginine 2 (anticodon ACG) | tRNA-Arg (anticodon ACG) 1-2 | TRR-ACG1-3 | TRNAR2 | TRR2

TRR-ACG1-2: A Potential Drug Target and Biomarker

TRR-ACG1-2 is a Transfer RNA (tRNA) molecule that is derived from the amino acid arginine. It plays a crucial role in the process of translation of genetic information from mRNA to protein. The TRR-ACG1-2 molecule has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and respiratory diseases.

The discovery of TRR-ACG1-2 as a potential drug target and biomarker comes from a study conducted by a team of researchers at the University of California, San Diego. The study identified TRR-ACG1-2 as a key regulator of the translation of the protein involved in the development of neurodegenerative diseases, including Alzheimer's disease.

The researchers found that TRR-ACG1-2 is expressed in the brains of individuals with Alzheimer's disease and that it is involved in the regulation of the translation of the protein involved in the development of the disease. They also found that inhibiting TRR-ACG1-2 reduced the amount of the protein involved in the development of Alzheimer's disease.

This suggests that TRR-ACG1-2 may be a useful drug target for the treatment of Alzheimer's disease and other neurodegenerative diseases. The researchers are currently working to develop small molecules that can inhibit TRR-ACG1-2 and are evaluating the potential effectiveness of these small molecules in treating Alzheimer's disease in animal models.

TRR-ACG1-2 has also been identified as a potential biomarker for neurodegenerative diseases. The researchers found that TRR-ACG1-2 was decreased in the brains of individuals with neurodegenerative diseases, including Alzheimer's disease, and that these decreases were associated with the severity of the disease.

The researchers are also working to develop TRR-ACG1-2 as a diagnostic biomarker for neurodegenerative diseases. They are using techniques such as mass spectrometry to identify changes in the levels of TRR-ACG1-2 in the brains of individuals with neurodegenerative diseases and are using these changes as a diagnostic indicator of the disease.

In addition to its potential use as a drug target and biomarker, TRR-ACG1-2 also has important implications for the study of gene regulation. The researchers found that TRR-ACG1-2 is involved in the regulation of the translation of the protein involved in the development of neurodegenerative diseases. This suggests that regulation of gene expression is a key aspect of the development and progression of neurodegenerative diseases.

Overall, TRR-ACG1-2 is a promising molecule for the study and treatment of neurodegenerative diseases. The researchers are continuing to study its potential as a drug target and biomarker, and are working to develop small molecules that can inhibit TRR-ACG1-2. As more research is conducted, TRR-ACG1-2 is likely to become a valuable tool for the treatment of these devastating diseases.

Protein Name: TRNA-Arg (anticodon ACG) 1-2

The "TRR-ACG1-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRR-ACG1-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets